Evidence map›Paper›PMID 28963102›Full record

SynthesisJournal of the American Heart Association2017

Comprehensive Metabolomic Profiling and Incident Cardiovascular Disease: A Systematic Review.

Miguel Ruiz-Canela, Adela Hruby, Clary B Clish, Liming Liang, Miguel A Martínez-González, Frank B Hu

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 6 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 6 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Miguel Ruiz-CanelaDepartment of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.
Adela HrubyDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Clary B ClishThe Broad Institute of MIT and Harvard, Cambridge, MA.
Liming LiangDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Miguel A Martínez-GonzálezDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA mamartinez@unav.es.
Frank B HuDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Harvard University · USUniversidad de Navarra · ESBrigham and Women's Hospital · USBroad Institute · US

Funding

Mediterranean diet, Metabolites, and Cardiovascular DiseaseR01HL118264 · NHLBI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI HU, FRANK B, LAMUELA-RAVENTÓS, ROSA · 2013 to 2025
$6.8M
Dietary Interventions, Metabolites, and Risk of Type 2 DiabetesR01DK102896 · NIDDK · HARVARD SCHOOL OF PUBLIC HEALTH · PI HU, FRANK B, MARTINEZ GONZALEZ, MIGUEL A. · 2014 to 2017
$1.9M
NHLBI NIH HHS R01 HL118264NIDDK NIH HHS R01 DK102896
6 · The paper itself

Abstract

backgroundMetabolomics is a promising tool of cardiovascular biomarker discovery. We systematically reviewed the literature on comprehensive metabolomic profiling in association with incident cardiovascular disease (CVD). METHODS AND

resultsWe searched MEDLINE and EMBASE from inception to January 2016. Studies were eligible if they pertained to adult humans; followed an agnostic and/or comprehensive approach; used serum or plasma (not urine or other biospecimens); conducted metabolite profiling at baseline in the context of examining prospective disease; and included myocardial infarction, stroke, and/or CVD death in the CVD outcome definition. We identified 12 original articles (9 cohort and 3 nested case-control studies); participant numbers ranged from 67 to 7256. Mass spectrometry was the predominant analytical method. The number and chemical diversity of metabolites were very heterogeneous, ranging from 31 to >10 000 features. Four studies used untargeted profiling. Different types of metabolites were associated with CVD risk: acylcarnitines, dicarboxylacylcarnitines, and several amino acids and lipid classes. Only tiny improvements in CVD prediction beyond traditional risk factors were observed using these metabolites (C index improvement ranged from 0.006 to 0.05).

conclusionsThere are a limited number of longitudinal studies assessing associations between comprehensive metabolomic profiles and CVD risk. Quantitatively synthesizing the literature is challenging because of the widely varying analytical tools and the diversity of methodological and statistical approaches. Although some results are promising, more research is needed, notably standardization of metabolomic techniques and statistical approaches. Replication and combinations of novel and holistic methodological approaches would move the field toward the realization of its promise.

Indexed as

Energy MetabolismMetabolomicsBiomarkersCardiovascular DiseasesHumansIncidenceMass SpectrometryPredictive Value of TestsPrognosisReproducibility of ResultsRisk FactorsBiomarkersepidemiologymetabolomicsmyocardial infarctionstroke

Identifiers

PMID28963102
PMCPMC5721826
OpenAlexW2760801784

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.